OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Recommendation of “Hold” from Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have been given a consensus recommendation of “Hold” by the five brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $5.6667.

A number of equities analysts recently commented on OKYO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a research note on Tuesday, April 21st. HC Wainwright cut their price target on OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, July 13th.

OKYO Pharma Stock Performance

NASDAQ OKYO opened at $1.43 on Monday. The firm’s 50 day moving average price is $1.59 and its 200-day moving average price is $1.76. OKYO Pharma has a 52-week low of $1.34 and a 52-week high of $3.35.

Institutional Investors Weigh In On OKYO Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its position in OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after acquiring an additional 96,800 shares during the last quarter. XTX Topco Ltd purchased a new position in OKYO Pharma in the fourth quarter worth $36,000. Finally, Citadel Advisors LLC purchased a new position in OKYO Pharma in the third quarter worth $31,000. Hedge funds and other institutional investors own 2.97% of the company’s stock.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.